Correlation Between Incyte and Akero Therapeutics
Can any of the company-specific risk be diversified away by investing in both Incyte and Akero Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Incyte and Akero Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Incyte and Akero Therapeutics, you can compare the effects of market volatilities on Incyte and Akero Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Incyte with a short position of Akero Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Incyte and Akero Therapeutics.
Diversification Opportunities for Incyte and Akero Therapeutics
0.8 | Correlation Coefficient |
Very poor diversification
The 3 months correlation between Incyte and Akero is 0.8. Overlapping area represents the amount of risk that can be diversified away by holding Incyte and Akero Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Akero Therapeutics and Incyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Incyte are associated (or correlated) with Akero Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Akero Therapeutics has no effect on the direction of Incyte i.e., Incyte and Akero Therapeutics go up and down completely randomly.
Pair Corralation between Incyte and Akero Therapeutics
Given the investment horizon of 90 days Incyte is expected to generate 9.47 times less return on investment than Akero Therapeutics. But when comparing it to its historical volatility, Incyte is 2.71 times less risky than Akero Therapeutics. It trades about 0.01 of its potential returns per unit of risk. Akero Therapeutics is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest 3,816 in Akero Therapeutics on August 24, 2024 and sell it today you would lose (543.00) from holding Akero Therapeutics or give up 14.23% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Strong |
| Accuracy | 100.0% |
| Values | Daily Returns |
Incyte vs. Akero Therapeutics
Performance |
| Timeline |
| Incyte |
| Akero Therapeutics |
Incyte and Akero Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Incyte and Akero Therapeutics
The main advantage of trading using opposite Incyte and Akero Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Incyte position performs unexpectedly, Akero Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will offset losses from the drop in Akero Therapeutics' long position.| Incyte vs. Alnylam Pharmaceuticals | Incyte vs. United Therapeutics | Incyte vs. Ultragenyx | Incyte vs. Apellis Pharmaceuticals |
| Akero Therapeutics vs. Lyra Therapeutics | Akero Therapeutics vs. Hookipa Pharma | Akero Therapeutics vs. Cingulate Warrants | Akero Therapeutics vs. SAB Biotherapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Complementary Tools
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |